Hormonal
GLP-1 receptor agonists (specifically semaglutide and liraglutide) significantly reduce hepatic fat content and resolve NASH in patients with NAFLD, primarily through delayed gastric emptying and direct metabolic effects on the liver.
If you have NAFLD or NASH, especially if you are overweight or have type 2 diabetes, GLP-1 receptor agonists like semaglutide (once weekly) and liraglutide are currently the most promising pharmacological treatments for resolving liver fat and NASH. While they can cause temporary gastrointestinal issues like nausea, clinical trials show they significantly improve liver outcomes compared to placebo. Discuss these options with your doctor, as they may offer resolution of steatosis and metabolic improvement.
Semaglutide is the GLP-1 receptor agonist that has shown a clinically relevant reduction of BW in overweight or obese patients treated with a once-weekly 2.4 mg dose... When Semaglutide was evaluated in NASH patients, Newsome et al. observed a significantly higher percentage of patients with NASH resolution than placebo (p <0.001 for Semaglutide 0.4 mg vs. placebo)... Liraglutide has been studied as adjuvant therapy... specifically in NAFLD patients, in the LEAN study, liraglutide showed resolution of steatosis, as well as metabolic improvement when it was compared with placebo.
Why this rating
The paper cites randomized clinical trials (Newsome et al., LEAN study) showing statistically significant results, though it notes more evidence is needed for fibrosis resolution.
Source
Hunger & satiety signals: another key mechanism involved in the NAFLD pathway
Iván López-Méndez et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1213372
More from this paper
- Ghrelin levels, specifically the ratio of unacylated to acylated ghrelin, are altered in NAFLD patients, with decreased plasma unacylated/acylated ghrelin ratio and increased hypothalamic acylated ghrelin expression correlating with insulin resistance and NAFLD severity.Moderate
- Bariatric surgery (BS) improves NAFLD outcomes by altering bile acid bioavailability, which activates the Fxr-Glp-1 axis, improves glucose homeostasis, and reestablishes normal ghrelin responses.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →